Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the ...

Metabolic reprogramming in fibrotic lung diseases involves key metabolites like lactate, succinate, and 2-hydroxyglutarate, ...

Type 2 diabetes (T2D) is a chronic metabolic disorder characterised by insulin resistance and impaired insulin secretion, ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for major cardiovascular events and for all-cause mortality, according to a new analysis of real-world ...